Literature DB >> 21984699

The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development.

Iris Castro1, Aixin Yu, Michael J Dee, Thomas R Malek.   

Abstract

Recent work suggests that IL-2 and IL-15 induce distinctive levels of signaling through common receptor subunits and that such varied signaling directs the fate of Ag-activated CD8(+) T cells. In this study, we directly examined proximal signaling by IL-2 and IL-15 and CD8(+) T cell primary and memory responses as a consequence of varied CD122-dependent signaling. Initially, IL-2 and IL-15 induced similar p-STAT5 and p-S6 activation, but these activities were only sustained by IL-2. Transient IL-15-dependent signaling is due to limited expression of IL-15Rα. To investigate the outcome of varied CD122 signaling for CD8(+) T cell responses in vivo, OT-I T cells were used from mouse models where CD122 signals were attenuated by mutations within the cytoplasmic tail of CD122 or intrinsic survival function was provided in the absence of CD122 expression by transgenic Bcl-2. In the absence of CD122 signaling, generally normal primary response occurred, but the primed CD8(+) T cells were not maintained. In marked contrast, weak CD122 signaling supported development and survival of T central-memory (T(CM)) but not T effector-memory (T(EM)) cells. Transgenic expression of Bcl-2 in CD122(-/-) CD8(+) T cells also supported the survival and persistence of T(CM) cells but did not rescue T(EM) development. These data indicate that weak CD122 signals readily support T(CM) development largely through providing survival signals. However, stronger signals, independent of Bcl-2, are required for T(EM) development. Our findings are consistent with a model whereby low, intermediate, and high CD122 signaling support T(CM) memory survival, T(EM) programming, and terminal T effector cell differentiation, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984699      PMCID: PMC3304468          DOI: 10.4049/jimmunol.1003961

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment.

Authors:  Roberto Carrio; Oliver F Bathe; Thomas R Malek
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

3.  Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival.

Authors:  Timothy W Hand; Weiguo Cui; Yong Woo Jung; Esen Sefik; Nikhil S Joshi; Anmol Chandele; Ying Liu; Susan M Kaech
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

4.  CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen.

Authors:  J M Curtsinger; D C Lins; M F Mescher
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

5.  Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein Kinase/c-Jun N-terminal kinase) activation. IL-2-driven proliferation is independent of p38 and p54 MAP kinase activation.

Authors:  A E Hunt; F V Lali; J D Lord; B H Nelson; T Miyazaki; K J Tracey; B M Foxwell
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

6.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

Authors:  J P Lodolce; D L Boone; S Chai; R E Swain; T Dassopoulos; S Trettin; A Ma
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

Review 7.  Biology of the interleukin-2 receptor.

Authors:  B H Nelson; D M Willerford
Journal:  Adv Immunol       Date:  1998       Impact factor: 3.543

8.  Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta.

Authors:  H Suzuki; T M Kündig; C Furlonger; A Wakeham; E Timms; T Matsuyama; R Schmits; J J Simard; P S Ohashi; H Griesser
Journal:  Science       Date:  1995-06-09       Impact factor: 47.728

9.  Characterization of B-cell lines established from two X-linked severe combined immunodeficiency patients: interleukin-15 binds to the B cells but is not internalized efficiently.

Authors:  S Kumaki; H D Ochs; M Timour; K Schooley; M Ahdieh; H Hill; K Sugamura; D Anderson; Q Zhu; D Cosman
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains.

Authors:  A Hémar; A Subtil; M Lieb; E Morelon; R Hellio; A Dautry-Varsat
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  38 in total

1.  Visualization of granzyme B-expressing CD8 T cells during primary and secondary immune responses to Listeria monocytogenes.

Authors:  Pierre Mouchacca; Lionel Chasson; Melissa Frick; Chloé Foray; Anne-Marie Schmitt-Verhulst; Claude Boyer
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

2.  IL-15 receptor α signaling constrains the development of IL-17-producing γδ T cells.

Authors:  Sara L Colpitts; Lynn Puddington; Leo Lefrançois
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

Review 3.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

4.  Stable inhibitory activity of regulatory T cells requires the transcription factor Helios.

Authors:  Hye-Jung Kim; R Anthony Barnitz; Taras Kreslavsky; Flavian D Brown; Howell Moffett; Madeleine E Lemieux; Yasemin Kaygusuz; Torsten Meissner; Tobias A W Holderried; Susan Chan; Philippe Kastner; W Nicholas Haining; Harvey Cantor
Journal:  Science       Date:  2015-10-16       Impact factor: 47.728

5.  Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.

Authors:  C Bryce Johnson; Brian P Riesenberg; Bennett R May; Stuart C Gilreath; Guangfu Li; Kevin F Staveley-O'Carroll; Elizabeth Garrett-Mayer; Shikhar Mehrotra; David J Cole; Mark P Rubinstein
Journal:  Cancer Immunol Res       Date:  2015-08-21       Impact factor: 11.151

6.  Cdk5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex.

Authors:  Eric Lam; Tej K Pareek; John J Letterio
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.

Authors:  Connor J Dwyer; Allison L Bayer; Carmen Fotino; Liping Yu; Cecilia Cabello-Kindelan; Natasha C Ward; Kevin H Toomer; Zhibin Chen; Thomas R Malek
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

8.  Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.

Authors:  Chie Hotta-Iwamura; Charles Benck; William D Coley; Yi Liu; Yongge Zhao; Juan A Quiel; Kristin V Tarbell
Journal:  J Autoimmun       Date:  2018-02-10       Impact factor: 7.094

9.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Authors:  Yumeng Mao; Vincent van Hoef; Xiaonan Zhang; Erik Wennerberg; Julie Lorent; Kristina Witt; Laia Masvidal; Shuo Liang; Shannon Murray; Ola Larsson; Rolf Kiessling; Andreas Lundqvist
Journal:  Blood       Date:  2016-07-27       Impact factor: 22.113

Review 10.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Authors:  Wei Liao; Jian-Xin Lin; Warren J Leonard
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.